Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

NCT03058094 is registered in ClinicalTrials.gov with Hangzhou ACEA Pharmaceutical Research Co., Ltd. as lead sponsor.

NCT NCT03058094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03058094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Lead sponsor
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase
Phase 3
Overall status
Withdrawn
Start date
December 31, 2018
Completion date
January 31, 2020
Enrollment
0 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc